Cerus (NASDAQ:CERS) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Monday, March 4th. ValuEngine raised shares of Cerus from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Cerus in a research note on Tuesday, December 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $8.50.

CERS stock opened at $6.12 on Friday. The stock has a market capitalization of $855.96 million, a PE ratio of -13.91 and a beta of 1.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.79 and a quick ratio of 2.53. Cerus has a 12 month low of $4.70 and a 12 month high of $8.05.

Cerus (NASDAQ:CERS) last posted its earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $16.50 million during the quarter, compared to the consensus estimate of $18.74 million. Cerus had a negative return on equity of 65.35% and a negative net margin of 84.15%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted ($0.10) EPS. As a group, analysts anticipate that Cerus will post -0.42 EPS for the current year.

In other news, SVP Carol Moore sold 10,886 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $6.01, for a total value of $65,424.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Dennis Green sold 23,524 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $2.05, for a total value of $48,224.20. Following the completion of the transaction, the chief financial officer now directly owns 66,825 shares of the company’s stock, valued at approximately $136,991.25. The disclosure for this sale can be found here. Insiders sold 57,647 shares of company stock valued at $254,880 in the last ninety days. 6.80% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in CERS. Norges Bank acquired a new position in shares of Cerus in the fourth quarter valued at approximately $12,997,000. Millennium Management LLC increased its stake in shares of Cerus by 118.1% in the fourth quarter. Millennium Management LLC now owns 1,267,355 shares of the biotechnology company’s stock valued at $6,425,000 after buying an additional 686,333 shares during the period. PNC Financial Services Group Inc. acquired a new position in shares of Cerus in the third quarter valued at approximately $4,815,000. FMR LLC increased its stake in shares of Cerus by 52,232.7% in the fourth quarter. FMR LLC now owns 647,356 shares of the biotechnology company’s stock valued at $3,282,000 after buying an additional 646,119 shares during the period. Finally, Elk Creek Partners LLC increased its stake in shares of Cerus by 11.4% in the fourth quarter. Elk Creek Partners LLC now owns 5,755,232 shares of the biotechnology company’s stock valued at $29,179,000 after buying an additional 586,820 shares during the period. 65.15% of the stock is owned by institutional investors.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Recommended Story: Buy-Side Analysts

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.